Get the Stockscreener App
3.11
8.26%
-0.28
After Hours:
3.17
0.06
+1.93%
Bioxcel Therapeutics Inc stock is traded at $3.11, with a volume of 2.54M.
It is down -8.26% in the last 24 hours and down -54.26% over the past month.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
See More
Previous Close:
$3.39
Open:
$3.39
24h Volume:
2.54M
Relative Volume:
0.28
Market Cap:
$49.79M
Revenue:
$1.38M
Net Income/Loss:
$-179.05M
P/E Ratio:
-0.5065
EPS:
-6.14
Net Cash Flow:
$-155.03M
1W Performance:
-17.94%
1M Performance:
-54.26%
6M Performance:
+27.98%
1Y Performance:
+465.45%
1-Day Range:
$3.09
$3.41
1-Week Range:
$3.09
$4.29
52-Week Range:
$0.16
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Name
Bioxcel Therapeutics Inc
Sector
Industry
Phone
203-643-8060
Address
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
3.11 | 56.35M | 1.38M | -179.05M | -155.03M | -6.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-24 | Downgrade | UBS | Buy → Neutral |
| Aug-15-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-10-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-01-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-06-22 | Reiterated | BofA Securities | Buy |
| Nov-15-21 | Downgrade | Goldman | Neutral → Sell |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-30-20 | Initiated | Goldman | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Aug-17-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-04-20 | Initiated | Guggenheim | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
View All
Bioxcel Therapeutics Inc Stock (BTAI) Latest News
BioXcel Therapeutics stock price target raised to $4 by Mizuho on positive trial data - Investing.com Canada
BioXcel Therapeutics Reports Positive Phase 3 Trial Results - MSN
BioXcel reports positive efficacy data for at-home agitation treatment - Investing.com India
Murchinson Ltd. Takes $276,000 Position in BioXcel Therapeutics, Inc. $BTAI - MarketBeat
Transcript : BioXcel Therapeutics, Inc.Special Call - MarketScreener
Bioxcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study - Menafn.com
BioXcel Therapeutics : SERENITY AT Home Topline September 10 - MarketScreener
BioXcel reports positive efficacy data for at-home agitation treatment By Investing.com - Investing.com Canada
BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study - Stocktwits
BioXcel Therapeutics Reports Positive Topline Exploratory - GlobeNewswire
BioXcel Therapeutics, Inc. Reports Positive Topline Exploratory Efficacy Data from Serveity At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia - MarketScreener
BioXcel Therapeutics at H.C. Wainwright: Expanding IGALMI’s Reach By Investing.com - Investing.com Canada
BioXcel Therapeutics at H.C. Wainwright: Expanding IGALMI’s Reach - Investing.com
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Update - MarketBeat
BioXcel Therapeutics Receives Positive FDA Feedback - MSN
Can momentum traders help lift BioXcel Therapeutics Inc.Weekly Market Summary & Fast Entry and Exit Trade Plans - Newser
Technical signs of recovery in BioXcel Therapeutics Inc.Insider Selling & Daily Chart Pattern Signal Reports - Newser
Canaccord Genuity Reaffirms Their Buy Rating on Bioxcel Therapeutics (BTAI) - The Globe and Mail
Is BioXcel Therapeutics Inc. part of any major indexJuly 2025 Macro Moves & Verified Swing Trading Watchlist - خودرو بانک
Published on: 2025-09-05 14:41:42 - Newser
Using data models to predict BioXcel Therapeutics Inc. stock movementSwing Trade & Weekly Watchlist for Hot Stocks - Newser
Can machine learning forecast BioXcel Therapeutics Inc. recoveryTrade Risk Report & Fast Entry High Yield Stock Tips - Newser
Can a trend reversal in BioXcel Therapeutics Inc. lead to recovery2025 Earnings Impact & Precise Swing Trade Alerts - Newser
What candlestick patterns are forming on BioXcel Therapeutics Inc.Earnings Overview Report & Fast Momentum Stock Entry Tips - Newser
Using Bollinger Bands to evaluate BioXcel Therapeutics Inc.July 2025 Retail & Real-Time Chart Pattern Alerts - Newser
Sector ETF performance correlation with BioXcel Therapeutics Inc.Weekly Market Summary & Comprehensive Market Scan Insights - Newser
How cyclical is BioXcel Therapeutics Inc.’s revenue stream2025 Pullback Review & Reliable Trade Execution Plans - خودرو بانک
Is BioXcel Therapeutics Inc. stock poised for growthWeekly Profit Recap & Weekly Breakout Watchlists - Newser
Will BioXcel Therapeutics Inc. see short term momentumQuarterly Market Summary & Verified Swing Trading Watchlist - Newser
Published on: 2025-09-04 06:34:10 - Newser
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
AI-Driven Neuroscience Biotech BioXcel Therapeutics to Showcase Pipeline at Global Investment Conference - Stock Titan
BioXcel Therapeutics announces SERENITY Phase 3 trial met primary endpoint - MSN
Trend analysis for BioXcel Therapeutics Inc. this weekWeekly Profit Analysis & Growth Focused Investment Plans - Newser
Is BioXcel Therapeutics Inc. reversing from oversold territoryMarket Volume Summary & Low Risk Profit Maximizing Plans - Newser
Is BioXcel Therapeutics Inc. a speculative investmentMarket Trend Review & Target Return Focused Picks - خودرو بانک
BioXcel's agitation drug meets main goal in at-home study - MSN
What’s next for BioXcel Therapeutics Inc. stock2025 Fundamental Recap & Daily Chart Pattern Signals - خودرو بانک
What Fibonacci levels say about BioXcel Therapeutics Inc. reboundJuly 2025 Pullbacks & Safe Capital Growth Plans - Newser
Custom strategy builders for tracking BioXcel Therapeutics Inc.Portfolio Performance Summary & Long-Term Capital Growth Ideas - Newser
Is it too late to sell BioXcel Therapeutics Inc.Weekly Stock Report & Daily Volume Surge Trade Alerts - Newser
Will BioXcel Therapeutics Inc. stock recover after recent dropEarnings Summary Report & Daily Stock Momentum Reports - Newser
Risk vs reward if holding onto BioXcel Therapeutics Inc.Market Movement Recap & Step-by-Step Trade Execution Guides - Newser
Is BioXcel Therapeutics Inc. a strong candidate for buy and hold2025 Support & Resistance & Precise Swing Trade Alerts - khodrobank.com
Detecting price anomalies in BioXcel Therapeutics Inc. with AIAnalyst Upgrade & Growth Oriented Trading Recommendations - Newser
BioXcel Therapeutics Inc. stock momentum explained2025 Institutional Moves & Accurate Trade Setup Notifications - Newser
Risk adjusted return profile for BioXcel Therapeutics Inc. analyzedRecession Risk & Low Drawdown Investment Ideas - Newser
BioXcel Therapeutics' (BTAI) Buy Rating Reiterated at HC Wainwright - MarketBeat
Will BioXcel Therapeutics Inc. outperform the marketTrade Exit Summary & Consistent Growth Stock Picks - Newser
Will BioXcel Therapeutics Inc. benefit from green energy policies2025 Short Interest & Reliable Volume Spike Alerts - خودرو بانک
BioXcel shares rise on positive Phase 3 safety trial results - MSN
Bioxcel Therapeutics Inc Stock (BTAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):